| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2140169 | Leukemia Research | 2006 | 13 Pages |
Abstract
Etodolac induced loss of mitochondrial membrane potential and apoptosis via a COX-2-independent pathway, suppressed the expression of adhesion molecules, and inhibited myeloma cell adhesion to BMSCs compared with thalidomide or meloxicam. The activities of etodolac potentially extend to the treatment of patients with myeloma resistant to standard chemotherapy, including thalidomide.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Satoki Nakamura, Miki Kobayashi, Kiyoshi Shibata, Naohi Sahara, Kazuyuki Shigeno, Kaori Shinjo, Kensuke Naito, Hideharu Hayashi, Kazunori Ohnishi,